14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CALA ranks #16625 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Calithera Biosciences Stock Forecast NASDAQ:CALA

$0.72 (-10.25%)

Volume: 1M

Closed: Dec 03, 2021

Hollow Logo Score: -5.893

Calithera Biosciences Stock Forecast

$0.72 (-10.25%)

Volume: 1M

Closed: Dec 03, 2021

Score Hollow Logo -5.893
Which way will CALA go? Request
Key Stats
Beta 1.27
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] The Calithera Biosciences stock currently holds an RSI14 at 24 and is oversold on RSI14. The stock being oversold is no guarantee for instant reaction up as some stocks may be oversold for a long time. It is important to review the previous RSI-history to get an indication of the RSI-sensitiveness.

High volatility in Calithera Biosciences stock price on Friday which ended trading at $0.72
(Updated on Dec 03, 2021)

Sell candidate since 2021-10-18 Loss -64.37%

The Calithera Biosciences stock price fell by -10.25% on the last day (Friday, 3rd Dec 2021) from $0.80 to $0.72. During the day the stock fluctuated 13.77% from a day low at $0.70 to a day high of $0.80. The price has fallen in 7 of the last 10 days and is down by -25.28% for this period. Volume has increased on the last day by 296 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 1 million shares were bought and sold for approximately $748.78 thousand.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -63.53% during the next 3 months and, with a 90% probability hold a price between $0.13 and $0.36 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Calithera Biosciences stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $0.82 and $1.33. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Tuesday, November 16, 2021, and so far it has fallen -29.09%. Further fall is indicated until a new bottom pivot has been found. Calithera Biosciences gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs".

Support, Risk & Stop-loss

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.0966 between high and low, or 13.77%. For the last week, the stock has had a daily average volatility of 10.30%.

Calithera Biosciences is oversold on RSI14 (24). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Calithera Biosciences stock A Buy?

Calithera Biosciences holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -5.893

Predicted Opening Price for Calithera Biosciences of Monday, December 6, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 6, 2021 Current price
$0.74 $0.72 (Undervalued)
Strong Sell Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 08, 2021 "HC Wainwright" gave "" rating for CALA. The price target was set to $0.86+0.0%.

Volatility and Risk
Daily Average Volatility: 10.30 %
Overall Risk: Very High High Medium Low Very Low
10.30 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $0.82
Price: $0.72
No Support Found

CALA Insider Trading Show all Trades



Last 100 transactions
Buy: 7 180 112 | Sell: 2 646 913 (Shares)
Date Action Amount Person Type
Nov 11, 2021 Sell 48 190 Orford Keith Common Stock
Nov 10, 2021 Sell 30 000 Orford Keith Common Stock
Nov 10, 2021 Buy 100 000 Molineaux Susan Common Stock
Nov 10, 2021 Buy 200 000 Drachman Jonathan G Common Stock
Nov 10, 2021 Buy 100 000 Molineaux Christopher Common Stock
Show all Insider Trades


Last 100 transactions
Buy: 7 180 112 | Sell: 2 646 913 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 0.84 16.61 %
0.80 11.45 %
0.78 8.27 %
Current price: 0.72
Support 0.70 -2.03 %
0.68 -5.22 %
0.64 -10.37 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 0.88 22.62 %
0.86 20.47 %
0.82 14.51 %
Current price 0.72
Support 0 .
0 .
0 .

Click to get the best stock tips daily for free!

About Calithera Biosciences

Calithera Biosciences Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myelom... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE